A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

NCT04551586 PHASE1 COMPLETED

This will be an open-label, 3-sequence, 3-period crossover study in healthy adult participants to assess the relative bioavailability of ACH-0145228 when administered as an immediate release tablet versus powder-in-capsule.

Details

Lead sponsor	Alexion Pharmaceuticals, Inc.
Phase	PHASE1
Status	COMPLETED
Enrolment	28
Start date	Fri Jun 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Oct 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy

Interventions

• ACH-0145228: Immediate Release
• ACH-0145228: Powder-in-capsule

Countries

United States